Incidence and survival rates
Renal cancer is the 12th most common malignancy worldwide (338,000 new cases diagnosed in 2012) with 6,474 new cases diagnosed in 2012 in Spain [1]. It occurs more often in men than in woman (age-standardized ratios for both incidence and mortality are 50 % higher in man compared with woman). Worldwide incidence of all stages has increased in recent years, 2 % yearly, and was responsible for over 143,469 deaths in 2012 [2].
Risk factors
Approximately 75 % of renal cancers are diagnosed over the age of 60, with a plateau reached around 70–75 years of age [2].
Anzeige
Smoking is a well-established risk factor for renal cancer with a meta-analysis reporting a clear difference between smokers and non-smokers and also a dose-dependent risk in number of cigarettes smoked [3]. Smoking cessation for more than 10 years may reduce the risk of RCC [4]. Obesity has also been established as a risk factor for RCC. A meta-analysis provided evidence for an association between body mass index and risk of RCC [5]. Several studies have demonstrated an inverse relationship between physical activity and RCC risk. Several cohort studies have reported an association with long-term hypertension and risk of RCC [6].
Approximately 2–3 % of RCCs are familial or hereditary [7] with a twofold increase incidence in a first-degree relative. Each histological subtype has a corresponding hereditary component caused by distinct genetic alteration. The most common hereditary syndrome for clear cell RCC is the von Hippel–Lindau (VHL) syndrome. Hereditary papillary RCC is associated exclusively with type 1 papillary RCC and does not present with manifestations in other organs. The familial leiomyomatosis and RCC syndrome have been correlated with mutations in the fumarate hydratase gene (FH) and patients present with type 2 papillary RCC. Lastly, in the Birt–Hogg–Dubé (BHD) syndrome, germ line mutations in the homonymous tumor suppressor folliculin gene are characteristic and patients present typically with chromophobe RCC, oncocytomas or hybrid tumors.
Pathological diagnosis/molecular biology
More than 50 % of RCCs are currently detected incidentally when imaging is being performed for some other reasons. However, still a large number of patients with RCC present with symptoms, such as flank pain, gross hematuria and palpable abdominal mass. This is considered the “classical triad” for diagnosis, nowadays infrequently seen together. Metastatic symptoms such as bone pain, dyspnea, cough or paraneoplastic syndromes such as hypercalcemia, unexplained fever, erythrocytosis or wasting syndromes are occasionally seen, being this the reason the name RCC as “the internist tumor”.
A core biopsy can provide the confirmation of malignancy with the specific histological type with high sensitivity and specificity. Biopsy is mandatory especially before the treatment with ablative or focal therapies [3, B]. It is also mandatory in patients with metastatic disease before starting any type of systemic treatment [3, B]. The final histopathological diagnosis, classification, grading and evaluation of prognostic factors are based on the nephrectomy specimen when available.
Anzeige
Different histological subtypes with specific genetic alterations have been identified with similar genetic alterations seen in the familial forms.
Clear cell renal cell carcinoma
Clear cell RCC (ccRCC) is the most common subtype of renal cancer, accounting for 75 % of all primary kidney tumors. These tumors have clear cytoplasm secondary to deposition of lipids and glycogen. Clear cell tumors are commonly hypervascular and can show coagulative tumor necrosis. The most characteristic feature seen in ccRCC is the inactivation of von Hippel–Lindau (VHL) tumor suppressor gene [8] reported in up to 75 %. Other commonly observed cytogenetic alterations in ccRCC include losses at 3p (90 %) 14q, 8p and 9p and gains at 12q and 5q [9]. Inactivation of several histone-modifying genes has been described, such as SETD2 (10–12 %), PBRM1 (40 %) and BAP1 (10 %) with suggested prognostic implications [10].
Papillary renal cell carcinoma
Papillary RCC types occur in 10–15 % of cases. Multifocal and synchronous bilateral cases are observed in 10 % of papillary RCC. Two subtypes are described: papillary type 1 and type 2.
Germ line met proto-oncogene (MET) and FH alterations are observed in the hereditary form of papillary 1 and in the hereditary leiomyomatosis (type 2), respectively. However, these genetic abnormalities are not frequently observed in the sporadic forms. Cytogenetic alterations in papillary RCC type 1 include gains of chromosomes 7, 8q, 12q, 16p, 17, 20 and loss of 9p. Papillary type 2 tumors gain 8q, lose 1p and 9p [11].
There are conflicting data on the differences/similarities in clinical behavior between papillary RCC type 1 and type 2. Nevertheless, the former appears to be associated with fewer aggressive features than the latter, including a lower stage and grade, as well as longer 5-year survival (~89–94 % versus 55–74 %) [12].
Chromophobe renal cell carcinoma
Chromophobe RCC occurs in 5 % of cases. This subtype has a less aggressive phenotype when compared with the other histological subtypes. Whether or not patients with chromophobe RCC have a better survival outcome than those with other histological subtypes is unclear. Chromophobe histology is present in 30 % of renal tumors seen in the hereditary Birt–Hogg–Dubé (BHD) syndrome [13]. This disease is associated with mutations in the BHD gene whose product is folliculin. Chromophobe tumors frequently have copy number alterations at chromosome 1, 2, 6, 10, 13 and 17. Strong staining for cell membrane-bound KIT protein has consistently been shown in chromophobe RCC tumors.
Sarcomatoid transformation
Sarcomatoid transformation is present in 5 % of RCC. Sarcomatoid components can occur in all histological subtypes of RCC and do not in themselves represent a distinct histological entity. It has been suggested that a cutoff of 30 % sarcomatoid features in the primary tumor may be useful in predicting systemic sarcomatoid histology. TP53 alterations occur in this dedifferentiation process [14].
Collecting duct renal cell carcinoma
Collecting duct RCCs account for less than 0.5 % of RCC. These tumors arise from the medullary distal nephron or Bellini ducts. Bellini ducts tumors are an aggressive histological subtype, and most patients have metastases at presentation. Cytogenetic abnormalities include losses at 1p, 8p, 9p and 16p and gains at 13q [15].
Anzeige
Other types
Other less common subtypes include renal translocation carcinomas.
This rare entity of renal translocation carcinomas was first observed in children and young adults but has also been reported in adults. This tumor is characterized by the translocation of Xp11.2, with the gene fusions involving the TFE3 transcription factor gene or TFEB. More than 10 additional histological subtypes have been defined which occur rarely. These include the unclassified RCC, medullary, multilocular cystic RCC, mucinous tubular and spindle cell carcinoma and carcinoma associated with end-stage renal disease. The last WHO classification should be used to classify histology in RCC.
Staging of RCC: prognostic models for risk assessment
Staging of RCC
The staging of renal cell carcinoma (RCC) should be done according to the TNM classification system (version 2009) [16] (Tables 1 and 2).
Table 1
AJCC TNM staging for RCC (7th ed.)
Primary tumor (T) | |
T0 | No evidence of primary tumor |
T1 | Tumor <7 cm in diameter and limited to kidney |
T1a | Tumor ≤4 cm in diameter and limited to kidney |
T1b | Tumor ≤4 cm but <7 cm and limited to kidney |
T2 | Tumor >7 cm in diameter and limited to kidney |
T2a | Tumor >7 cm but <10 cm in diameter and limited to the kidney |
T2b | Tumor >10 cm and limited to the kidney |
T3 | Tumor extends into major veins or perinephric tissues, but not beyond Gerota’s fascia |
T3a | Tumor directly invades perinephric tissues, but not beyond Gerota’s fascia |
T3b | Tumor grossly extends into vena cava below the diaphragm |
T3c | Tumor grossly extends into vena cava above diaphragm or invades wall of vena cava |
T4 | Tumor invades beyond Gerota’s fascia (including contiguous ipsilateral adrenal gland) |
Regional lymph nodes (N)a
| |
N0 | No regional lymph node metastasis |
N1 | Metastasis in regional lymph node (s) |
Distant metastasis (M) | |
M0 | No distant metastasis |
M1 | Distant metastasis |
Table 2
Stage grouping for RCC Based on AJCC TNM stage and survival
Stage | T | N | M | 5-year OS (%) |
|---|---|---|---|---|
Stage I | T1 | N0 | M0 | 81 |
Stage II | T2 | N0 | M0 | 74 |
Stage III | T1, T2 | N1 | M0 | 53 |
T3 | Any N | M0 | ||
Stage IV | T4 | Any N | M0 | 10 |
Any T | Any N | M1 |
Anzeige
Evaluation of local disease
Computed tomography (CT) scan
The abdominal CT scan represents the gold standard in the staging of RCC and must be performed with and without intravenous [3, A] contrast and including images from the nephrographic phase. A change in 15 or more Hounsfield units before and after the contrast administration will be diagnostic of enhancement and suggesting malignancy. Abdominal CT imaging will provide relevant information for staging including: (1) degree of extension of primary tumor; (2) involvement of vasculature; (3) regional lymph nodes status; (4) adrenal gland and liver involvement; and (5) morphology and function of the contralateral kidney.
Magnetic resonance imaging (MRI)
Abdominal MRI is not performed routinely in the staging of RCC.
Indications of staging using MRI include: (1) allergy to CT iv contrast or pregnancy; (2) indeterminate results of CT regarding enhancement of complex renal masses; and (3) investigation of venous involvement when poor definition of inferior vena cava tumor thrombus in CT scan or investigation of locally advanced disease. Despite a high accuracy of both CT and MRI in RCC diagnosis, these tests are not able to reliably distinguish oncocytoma and fat-free angiomyolipoma from RCC [17].
Other imaging tests
Vascular imaging studies
Studies such as arteriography/venacavography will be utilized only in selected cases.
Radioisotope renography
Renal function evaluation studies should be considered when contemplating nephron-sparing strategies or if any sign of impaired renal function is present pre-surgery.
Positron emission tomography (PET)
There is no defined role for PET in diagnosis or follow-up of RCC. It should be considered investigational [1, B].
Evaluation of advanced disease
Chest imaging evaluation
In addition to the abdominal CT, the most accurate imaging test for chest staging is the chest CT that should be considered at initial staging [3, A]. An alternative is the chest X-ray [18].
Bone or brain studies
Outside a clinical trial, imaging studies of bone or brain should be performed only in the presence of symptoms or specific laboratory abnormalities [3, A] [19].
Risk assessment
Different variables including anatomical factors (i.e., size of the tumor, renal capsule invasion, venous invasion, adrenal and lymph node involvement), histological factors (i.e., RCC subtype, tumor necrosis and Fuhrman grade) and clinical factors (i.e., PS, cachexia, anemia, platelet count or local symptoms) are incorporated in prognostic models both in localized and metastatic disease. The UISS, SSIGN and the postoperative Karakiewicz’s nomogram are the most widely used prognostic models in localized disease [20‐22].
In the advanced setting, the MSKCC and the Heng classification are the two most spread prognostic models although others have also been developed [23, 24] (see Table 3).
Table 3
MSKCC or Heng risk criteria
MSKCC risk criteria (prognostic factors for poor OS) |
KPS <80 |
Diagnosis to therapy <1 year |
Anemia |
Hypercalcemia |
Elevated LDH |
0 factors: favorable risk |
1–2 factors: intermediate risk |
≥3 factors: poor risk |
Heng risk criteria for VEGF-targeted therapy [prognostic factors for poor overall survival (OS)] |
KPS <80 |
Diagnosis to therapy <1 year |
Anemia |
Hypercalcemia |
Neutrophilia |
Thrombocytosis |
0 factors: favorable risk |
1–2 factors: intermediate risk |
≥3 factors: poor risk |
While the MSKCC or Heng criteria should be routinely utilized in the treatment decision process of the patient with advanced RCC, the prognostic models in the localized setting remain investigational until data of prospective ongoing adjuvant studies are available.
Management of localized/resectable disease
Local disease
Surgery (nephrectomy) is the best approach with curative intention for localized RCC. Different techniques can be performed based on the extension of the resection (nephron sparing [NSS] or radical [RN]) or the approach (open vs. laparoscopic). For RCC tumors <4 cm, RN has been associated with increased mortality when compared with NSS. Therefore, RN is not recommended in this context unless a NSS is not technically feasible [25]. These outcomes have not been replicated in RCC tumors of 4–7 cm where partial and radical nephrectomy achieved similar cancer-specific survival and overall survival [26].
Anzeige
Regarding the approach, when compared with radical open surgery (ROS), radical laparoscopic nephrectomy (RLN) seems to have less surgical related complications although no differences in oncological outcomes have been demonstrated. Therefore, when a radical approach is recommended, RLN should be prioritized [27].
When analyzed by stage, RCC tumors stage 1 (T1) should be treated with a laparoscopic NSS if technically feasible. Stage 2 (T2) tumors should be handled with RLN. Stage III (T3, T4) tumors should be treated with open radical nephrectomy. Neither extended lymph node dissection nor adrenalectomy has shown added survival benefit and should not be performed routinely unless there is radiological or intraoperatory evidence of node involvement [28, 29].
Active surveillance (AS) (described as an initial watching of tumor size by successive abdominal imaging tests with deferred intervention reserved for those tumors that show clinical progression during follow-up) is an acceptable option in elderly and comorbid patients with small renal masses (<4 cm) detected incidentally as these masses tend to have a relatively low RCC-specific mortality [30].
Adjuvant treatment is not recommended in patients at high risk of relapse. Adjuvant trials with targeted therapies are ongoing or have completed accrual, and results are not yet available. Neo-adjuvant approaches are investigational and are not recommended in daily practice.
Management of advanced metastatic disease: first-line, second-line and therapeutic sequences––therapeutic algorithm
Role of surgery
In the era of cytokines, cytoreductive nephrectomy before systemic therapy was shown to provide a survival benefit in patients with good PS [I, A].
In the era of targeted therapies, we have retrospective evidence that cytoreductive nephrectomy can be of benefit in patients with good or intermediate risk or for patients with a symptomatic primary lesion [4, B]. Prospective trials are ongoing.
Metastasectomy can be considered in selected patients with solitary or limited number (≤4) of lung metastases and in solitary resectable metastases in other locations with long metachronous disease-free interval. It can also be considered in selected patients with stable responses to targeted therapies [31].
First-line treatment
The efficacy of sunitinib, bevacizumab plus interferon (IFN)-α [1, A], pazopanib [1, B] and temsirolimus [1, A] as first-line therapy was compared with either IFN-α or placebo in separate randomized phase III trials [32‐36]. Results showed that each of these targeted agents was superior to IFN-α in prolonging progression-free survival or overall survival times, or both. The majority of the patients in the sunitinib, pazopanib and bevacizumab plus IFN-α trials were in the favorable or intermediate MSKCC risk groups, and benefits relative to IFN-α were observed across groups. In the temsirolimus trial, all patients were classified by similar criteria as having a poor prognosis, which was equivalent to 74 % of patients being classified in the MSKCC poor-risk group and 26 % of patients being classified in the MSKCC intermediate-risk group.
The results of these trials prompted many changes in first-line therapy recommendations. Although Interferon plus bevacizumab have demonstrated similar impact than oral agents as a first-line therapy for metastatic RCC, oral monotherapy with a TK inhibitor has become the “de facto” standard of care in this situation.
Sunitinib has been the first agent showing high activity in first line. To date, three phase III trials have compared two different TKIs. After the phase III and the non-inferiority COMPARZ trials (median PFS 8.4 vs. 9.5 months with pazopanib and sunitinib, respectively), pazopanib has become an alternative option to sunitinib with some differences in toxicity profile, as first-line therapy for advanced or metastatic RCC [37]. In addition, two randomized trials have recently compared sorafenib with either tivozanib or axitinib. Tivozanib has become the first TKI that showed a benefit in terms of PFS in a phase III trial over another TKI, but was not approved because of its lack of impact in survival [38]. On the other hand, axitinib did not reach the pre-established target of the study, and the trial was prematurely discontinued [39].
Recommendations (clear cell histology)
1.
Sunitinib and pazopanib are best first-line treatment alternatives in metastatic RCC patients with good and intermediate risk (level of evidence: I; grade of recommendation: A and B, respectively).
2.
Bevacizumab combined with interferon is also an option, although it has been less used in favor of more convenient use of oral therapies (level of evidence: I; grade of recommendation: A).
3.
In patients with poor risk features, temsirolimus constitutes the first-line therapy (level of evidence: I; grade of recommendation: A), although sunitinib may also be an option for these patients (level of evidence: II; grade of recommendation: B).
4.
At this moment, first-line treatment with immunotherapy should not be recommended for patients with metastatic RCC (level of evidence: I; grade of recommendation: A).
5.
In highly selected fit patient population, high dose IL-2 could be considered (level of evidence: I; grade of recommendation: D).
Second-line treatment and therapeutic sequences
Based on a phase III study, the TKI sorafenib is approved for patients with advanced RCC, in whom cytokine therapy has failed or was not indicated [I, A] [40]. Sorafenib almost doubled PFS in second-line therapy compared to placebo (2.8 vs. 5.5 months). With axitinib, a second TKI has recently become available for the second-line therapy of patients after failure of first-line therapy with sunitinib or a cytokine [I, A]. In the AXIS study [41], PFS was increased by 2 months (6.7 vs. 4.7 months) with axitinib compared to sorafenib as reference [I, B]. Moreover, in second-line therapy, with everolimus an mTOR inhibitor can be used to treat these patients [II, A]. In the phase III RECORD-1 study, this agent was compared with placebo in patients after failure of at least 1 anti-VEGF therapy and increased median PFS (1.9 vs. 4.9 months) [42].
A phase III trial comparing an mTOR inhibitor, temsirolimus, with a second TKI, sorafenib, following progression on first-line sunitinib has been reported [43]. No differences in PFS were found (4.2 vs. 3.9 months). However, a significant advantage in OS in favor of sorafenib was observed (16.6 vs. 12.2 months; p = 0.014). The results of this study could be related to subsequent treatments administered, but unfortunately, these data are lacking. However, this finding and other retrospective studies [44] give more support to the sequence TKI after TKI. Nevertheless, mTOR inhibitors are also active after a second TKI and could be a good alternative in patients with severe toxicity on a previous TKI. Recently, a randomized phase II study that compared the sequence of first-line sunitinib followed by second-line everolimus with the reverse sequence showed a superiority in terms of PFS and OS favoring the sunitinib––everolimus sequence [45], suggesting that the order of administration of the agents is not irrelevant.
Recommendations
1.
After progression to first-line therapy with a TKI, sequential administration of alternative targeting agents should be considered (level of evidence: I; grade of recommendation: A). In this setting, both sequences either administering a second TKI or mTOR inhibitor are active therapeutic alternatives (level of evidence: I, B for everolimus and I, B for axitinib).
2.
Axitinib has been shown to be superior to sorafenib in second-line treatment (level of evidence: I; grade of recommendation: A), but sorafenib could be even consider an active option (level of evidence: IV; grade of recommendation: B).
3.
Sequential therapy with mTOR inhibitors should be considered in patients who progress after a second TKI (level of evidence: III; grade of recommendation: B) or in those patients who experienced poor tolerance to a first-line TKI (level of evidence: IV; grade of recommendation: B).
Treatment of metastatic non-clear cell histology
Some studies suggest now that patients with non-clear cell histology may benefit from treatment with sunitinib, sorafenib or temsirolimus [III, B]. The recent communication of ESPN trial (Tannir, N ASCO 2014) confirms that everolimus is not considered today the first option for therapy and still the optimal therapy remains unclear and warrants further study [46] (Table 4).
Table 4
Treatment algorithm
Treatment status | Setting | Category I evidence | Category II evidence |
|---|---|---|---|
Treatment naive (ccRCC) | Good intermediate risk | Sunitinib Bevacizumab/Interferon Pazopanib | Sorafenib High dose IL-2 |
Poor risk | Temsirolimus | Sunitinib Sorafenib | |
Second-line (ccRCC) | Cytokine refractory | Sorafenib Pazopanib Sunitinib Axitinib | |
TKI failure | Everolimus Axitinib | Sorafenib | |
Prior mTor inhibitors | Sunitinib | ||
Non-Clear Cell histology | Temsirolimus Everolimus Sunitinib Sorafenib |
Response evaluation and follow-up
Response evaluation
Currently, response evaluation in patients with advanced RCC is generally accepted to be performed every 8–12 weeks with CT chest–abdomen–pelvis as the method of choice. Response Evaluation Criteria in Solid Tumors (RECIST) is of limited utility in this setting but still remains the standard. Other imaging changes such as those integrated in the modified Choi criteria could be more accurate in correlating with clinical outcomes when using tyrosine kinase inhibitors. Special caution is needed when interpreting moderate size changes with density variations and no new lesions to avoid misinterpretation of progression in patients with advanced RCC [47, 48].
Follow-up
After definitive local treatment of RCC, there is no consensus about the best follow-up protocol. The most widely accepted approach is stratifying patients based on Fuhrman Grade, TNM Stage, ECOG and type of local treatment, in risk groups. Those patients considered with intermediate or high risk of relapse should be followed more intensively (3 versus 6 months imaging). CT of the chest–abdomen and pelvis is the imaging test of choice although no clear data about the proper timing and/or number of test per year is available (Table 5).
Table 5
Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America—United States Public Health Service Grading System)
Levels of evidence | |
I | Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomised trials without heterogeneity |
II | Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity |
III | Prospective cohort studies |
IV | Retrospective cohort studies or case–control studies |
V | Studies without control group, case reports, experts’ opinions |
Grades of recommendation | |
A | Strong evidence for efficacy with a substantial clinical benefit, strongly recommended |
B | Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended |
C | Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.), optional |
D | Moderate evidence against efficacy or for adverse outcome, generally not recommended |
E | Strong evidence against efficacy or for adverse outcome, never recommended |
Conflict of interest
J.B. Consultant for Pfizer, Novartis and GSK.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.